-

Schrödinger to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 12:30 p.m. ET on Tuesday, September 15, 2020.

A live webcast of the presentation can be accessed under "News & Events" in the investors section of Schrödinger’s website https://ir.schrodinger.com/news-and-events/event-calendar. A replay of the webcast will be available on Schrödinger’s website for 90 days following the event.

About Schrödinger

Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas.

Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com. Follow us on LinkedIn and Twitter.

Contacts

Media:
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

Investors:
Christina Tartaglia
Stern IR, Inc.
christina.tartaglia@sternir.com
212-362-1200

Industry:

Schrödinger

NASDAQ:SDGR
Release Summary
Schrödinger will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 12:30 pm ET on 9/13/2020
Release Versions
English

Contacts

Media:
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

Investors:
Christina Tartaglia
Stern IR, Inc.
christina.tartaglia@sternir.com
212-362-1200

More News From Schrödinger

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company’s common stock to three newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducem...

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

NEW YORK--(BUSINESS WIRE)--Schrödinger announced the formation of Tectora, a biotech it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies....

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi...
Back to Newsroom